Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer

Tomoyuki Kusumoto, Junichi Kodama, Noriko Seki, Keiichiro Nakamura, Atsushi Hongo, Yuji Hiramatsu

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Proteoglycans are ubiquitous components of the extracellular matrix and cell surface, and may mediate tumor progression and metastasis. The aim of this study was to evaluate the expression of syndecan-1 and versican in epithelial ovarian cancer. We immunohistochemically evaluated the expression of syndecan-1 and versican in 111 patients with epithelial ovarian cancer, and analyzed the correlation of this expression with various observed clinicopathological features, including patient outcome. There is a significant correlation between primary and metastatic sites with respect to syndecan-1 and versican expression. Epithelial syndecan-1 expression was significantly lower in patients with advanced disease. Epithelial versican expression was significantly higher in patients with early disease, especially in clear cell adenocarcinoma patients. Stromal syndecan-1 and versican expression was significantly higher in patients with advanced disease. Multivariate analysis showed that negative epithelial syndecan-1 expression was an independent prognostic factor for progression-free survival. Stromal syndecan-1 and versican co-expression was of borderline significance for progression-free and overall survival. Loss of epithelial syndecan-1 expression and induction of stromal syndecan-1 and versican expression may be associated with tumor progression in epithelial ovarian cancer. Syndecan-1 and versican expression status can serve as an indicator of prognosis in patients with epithelial ovarian cancer.

Original languageEnglish
Pages (from-to)917-925
Number of pages9
JournalOncology Reports
Volume23
Issue number4
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Versicans
Syndecan-1
Disease-Free Survival
Clear Cell Adenocarcinoma
Ovarian epithelial cancer
Proteoglycans
Extracellular Matrix
Neoplasms
Multivariate Analysis

Keywords

  • Epithelial ovarian cancer
  • Prognosis
  • Syndecan-1
  • Versican

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer. / Kusumoto, Tomoyuki; Kodama, Junichi; Seki, Noriko; Nakamura, Keiichiro; Hongo, Atsushi; Hiramatsu, Yuji.

In: Oncology Reports, Vol. 23, No. 4, 04.2010, p. 917-925.

Research output: Contribution to journalArticle

Kusumoto, Tomoyuki ; Kodama, Junichi ; Seki, Noriko ; Nakamura, Keiichiro ; Hongo, Atsushi ; Hiramatsu, Yuji. / Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer. In: Oncology Reports. 2010 ; Vol. 23, No. 4. pp. 917-925.
@article{19269fc37c6944118a7752f64c36cd1b,
title = "Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer",
abstract = "Proteoglycans are ubiquitous components of the extracellular matrix and cell surface, and may mediate tumor progression and metastasis. The aim of this study was to evaluate the expression of syndecan-1 and versican in epithelial ovarian cancer. We immunohistochemically evaluated the expression of syndecan-1 and versican in 111 patients with epithelial ovarian cancer, and analyzed the correlation of this expression with various observed clinicopathological features, including patient outcome. There is a significant correlation between primary and metastatic sites with respect to syndecan-1 and versican expression. Epithelial syndecan-1 expression was significantly lower in patients with advanced disease. Epithelial versican expression was significantly higher in patients with early disease, especially in clear cell adenocarcinoma patients. Stromal syndecan-1 and versican expression was significantly higher in patients with advanced disease. Multivariate analysis showed that negative epithelial syndecan-1 expression was an independent prognostic factor for progression-free survival. Stromal syndecan-1 and versican co-expression was of borderline significance for progression-free and overall survival. Loss of epithelial syndecan-1 expression and induction of stromal syndecan-1 and versican expression may be associated with tumor progression in epithelial ovarian cancer. Syndecan-1 and versican expression status can serve as an indicator of prognosis in patients with epithelial ovarian cancer.",
keywords = "Epithelial ovarian cancer, Prognosis, Syndecan-1, Versican",
author = "Tomoyuki Kusumoto and Junichi Kodama and Noriko Seki and Keiichiro Nakamura and Atsushi Hongo and Yuji Hiramatsu",
year = "2010",
month = "4",
doi = "10.3892/or-00000715",
language = "English",
volume = "23",
pages = "917--925",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer

AU - Kusumoto, Tomoyuki

AU - Kodama, Junichi

AU - Seki, Noriko

AU - Nakamura, Keiichiro

AU - Hongo, Atsushi

AU - Hiramatsu, Yuji

PY - 2010/4

Y1 - 2010/4

N2 - Proteoglycans are ubiquitous components of the extracellular matrix and cell surface, and may mediate tumor progression and metastasis. The aim of this study was to evaluate the expression of syndecan-1 and versican in epithelial ovarian cancer. We immunohistochemically evaluated the expression of syndecan-1 and versican in 111 patients with epithelial ovarian cancer, and analyzed the correlation of this expression with various observed clinicopathological features, including patient outcome. There is a significant correlation between primary and metastatic sites with respect to syndecan-1 and versican expression. Epithelial syndecan-1 expression was significantly lower in patients with advanced disease. Epithelial versican expression was significantly higher in patients with early disease, especially in clear cell adenocarcinoma patients. Stromal syndecan-1 and versican expression was significantly higher in patients with advanced disease. Multivariate analysis showed that negative epithelial syndecan-1 expression was an independent prognostic factor for progression-free survival. Stromal syndecan-1 and versican co-expression was of borderline significance for progression-free and overall survival. Loss of epithelial syndecan-1 expression and induction of stromal syndecan-1 and versican expression may be associated with tumor progression in epithelial ovarian cancer. Syndecan-1 and versican expression status can serve as an indicator of prognosis in patients with epithelial ovarian cancer.

AB - Proteoglycans are ubiquitous components of the extracellular matrix and cell surface, and may mediate tumor progression and metastasis. The aim of this study was to evaluate the expression of syndecan-1 and versican in epithelial ovarian cancer. We immunohistochemically evaluated the expression of syndecan-1 and versican in 111 patients with epithelial ovarian cancer, and analyzed the correlation of this expression with various observed clinicopathological features, including patient outcome. There is a significant correlation between primary and metastatic sites with respect to syndecan-1 and versican expression. Epithelial syndecan-1 expression was significantly lower in patients with advanced disease. Epithelial versican expression was significantly higher in patients with early disease, especially in clear cell adenocarcinoma patients. Stromal syndecan-1 and versican expression was significantly higher in patients with advanced disease. Multivariate analysis showed that negative epithelial syndecan-1 expression was an independent prognostic factor for progression-free survival. Stromal syndecan-1 and versican co-expression was of borderline significance for progression-free and overall survival. Loss of epithelial syndecan-1 expression and induction of stromal syndecan-1 and versican expression may be associated with tumor progression in epithelial ovarian cancer. Syndecan-1 and versican expression status can serve as an indicator of prognosis in patients with epithelial ovarian cancer.

KW - Epithelial ovarian cancer

KW - Prognosis

KW - Syndecan-1

KW - Versican

UR - http://www.scopus.com/inward/record.url?scp=77949451668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949451668&partnerID=8YFLogxK

U2 - 10.3892/or-00000715

DO - 10.3892/or-00000715

M3 - Article

C2 - 20204274

AN - SCOPUS:77949451668

VL - 23

SP - 917

EP - 925

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -